ADMA Biologics (ADMA) Set to Announce Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.13 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same quarter in the previous year, the business posted ($0.02) earnings per share. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $16.96 on Thursday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $3.93 billion, a price-to-earnings ratio of -848.00 and a beta of 0.62. ADMA Biologics has a twelve month low of $3.23 and a twelve month high of $21.13. The company has a 50-day simple moving average of $17.87 and a two-hundred day simple moving average of $13.22.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 over the last three months. Corporate insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.